Diabetic neuropathy is closely associated with arterial stiffening and thickness in Type 2 diabetes

Diabetic Medicine

Volumn 24, Issue 12, 2007, Pages 1329-1335

  Yokoyama, H ^a   Yokota, Y ^a   Tada, J ^a   Kanno, S ^a  

^a Jiyugaoka Medical Clinic   (Japan)

Author keywords

Arterial stiffening; Atherosclerosis; Diabetic neuropathy; Intima media thickness; Pulse wave velocity

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE;

ACHILLES REFLEX; ADULT; AGED; ALBUMINURIA; ARTERY COMPLIANCE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE PRESSURE; PULSE WAVE; SYSTOLIC BLOOD PRESSURE;

AGED; ALBUMINURIA; ARTERIOSCLEROSIS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CAROTID ARTERIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS; TUNICA INTIMA; TUNICA MEDIA;

EID: 36549030270     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02278.x     Document Type: Article

References (42)

1. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabete Metab Rev 1987 3 : 463 524.
2. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000 43 : 957 973.
3. Forsblom CM, Sane T, Groop PH. Risk factors for mortality in type II diabetes: evidence of a role for neuropathy and a prospective effect of HLA-DR4. Diabetologia 1998 41 : 1253 1262.
4. Coppini DV, Bowtell PA, Weng C, Young PJ, Sonksen PH. Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. J Clin Epidemiol, 2000 53 : 519 523.
5. Cameron NE, Eaton SEM, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001 44 : 1973 1988.
6. Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Manes C, Ionescu-Tirgoviste C et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005 352 : 341 350.
7. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q et al. Epidemiological correlates of diabetic neuropathy: report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989 38 : 1456 1461.
8. O'Leary DR, Polak JF, Kronmal RA. Distubution and correlates of sonographically detected carotid artery disease in the cardiovascular health study. Stroke 1992 23 : 1752 1760.
9. Bots ML, Hoes AW, Koudstaal PJ. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997 96 : 1432 1437.
10. van Popele NM, Grobbee DE, Bots ML. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke 2001 32 : 454 460.
11. Cruickshank K, Riste L, Anderson SG. Aortic pulse wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002 106 : 2085 2090.
12. Hansen TW, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006 113 : 664 670.
13. Yamashina A, Tomiyama H, Arai T. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003 26 : 615 622.
14. Yokoyama H, Aoki T, Imahori M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave. Kidney Int 2004 66 : 448 454.
15. Yokoyama H, Kuramitsu K, Kanno S, Tada J, Yokota Y, Kamikawa F. Relationship between metabolic syndrome components and vascular properties in Japanese type 2 diabetic patients without cardiovascular disease or nephropathy. Diabetes Res Clin Pract 2007 75 : 200 206.
16. Smith A, Karalliedde J, Angelis LD, Goldsmith D, Viberti G. Aortic pulse wave velocity and albuminuria in patientswith type 2 diabetes. J Am Soc Nephrol 2005 16 : 1069 1075.
17. Simone G, Roman MJ, Alderman MH, Galderisi M, Divitiis O, Devereux RB. Is high pulse pressure a marker of preclinical cardiovascular disease? Hypertension 2005 45 : 575 579.
18. Palmieri V, Devereux RB, Hollywood J, Bella JN, Liu JE, Lee ET et al. Association of pulse pressure with cardiovascular outcome is independent of left ventricular hypertrophy and systolic dysfunction: The Strong Heart Study. Am J Hypertens 2006 19 : 601 607.
19. Hotta N, Sugimura K, Tsuchida I, Sano T, Koh N, Matsumae H et al. Use of the C64 quantitative tuning fork and the effect of niceritol in diabetic neuropathy. Clin Ther 1994 16 : 1007 1015.
20. Hotta N, Yasuda K, Sumita Y, Sano T, Kakuta H, Nagashima M et al. Effects of a novel aldose reductase inhibitor, fidarestat (SNK-860), on vibration perception threshold and subjective symptoms in patients with diabetic polyneuropathy. Clin Drug Invest 2004 24 : 671 680.
21. Franklin GM, Shetterly SM, Cohen JA, Baxter J, Hamman RF. Risk factors for distal symmetric neuropathy in NIDDM: the San Luis Valley Diabetes Study. Diabetes Care 1994 17 : 1172 1177.
22. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ III., O'Brien PC. Risk factors for severity of diabetic polyneuropathy. Intensive longitudinal assessment of the Rochester Diabetic neuropathy Study Cohort. Diabetes Care 1999 22 : 1479 1486.
23. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993 36 : 150 154.
24. Kasuya Y, Ito M, Nakamura J, Hamada Y, Nakayama M, Chaya S et al. An aldose reductase inhibitor prevents the intimal thickening in coronary arteries of galactose-fed beagle dogs. Diabetologia 1999 42 : 1404 1409.
25. Witte DR, Tesfaye S, Chaturvedi N, Eaton SEM, Kempler P, Fuller JH, EURODIAB Prospective Complications Study Group. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005 48 : 164 171.
26. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997 157 : 1413 1418.
27. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 1989 32 : 219 226.
28. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003 26 : 1553 1579.
29. Toyry JP, Niskanen LK, Lansimies EA, Partanen KP, Uusitupa MI. Autonomic neuropathy predicts the development of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1996 27 : 1316 1318.
30. Marthol H, Brown CM, Zikeli U, Ziegler D, Dimitov N, Baltadzhieva R et al. Altered cerebral regulation in type 2 diabetic patients with cardiac autonomic neuropathy. Diabetologia 2006 49 : 2481 2487.
31. Spallone V, Gambardella S, Maiello MR, Barini A, Frontoni S, Menzinger G. Relationship between autonomic neuropathy, 24-hour blood pressure profile, and nephropathy in normotensive IDDM patients. Diabetes Care 1994 17 : 578 584.
32. Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006 29 : 334 339.
33. Moran A, Palmas W, Field L, Bhattarai J, Schwartz JE, Weinstock RS et al. Cardiovascular autonomic neuropathy is associated with microalbuminuria in older patients with type 2 diabetes. Diabetes Care, 2004 27 : 972 977.
34. Smulders YM, Jager A, Gerristen J, Dekker J, Nijpels G, Heine RJ et al. Cardiaovascular autonomic function is associated with (micro-) albuminuria in early Caucasian subjects with impaired glucose tolerance or type 2 diabetes. The Hoorn Study. Diabetes Care 2000 23 : 1369 1374.
35. Wiles PG, Pearce SM, Rice PJS, Mitchell JMO. Vibration perception threshold: influence of age, height, sex, and smoking, and calculation of accurate centile values. Diabet Med 1990 8 : 157 161.
36. Zureik M, Touboul PJ, Bonithon-Kopp C, Courbon D, Berr C, Leroux C et al. Cross-sectional and 4-year longitudinal associations between brachial pulse pressure and common carotid intima-media thickness in a general population. The EVA study. Stroke 1999 30 : 550 555.
37. Bots ML, Dijk JM, Oren A, Grobbee DE. Carotid intima-media thickness and risk of cardiovascular disease: current evidence. J Hypertens 2002 20 : 2317 2325.
38. Gottsater A, Ahlgren AR, Taimour S, Sunkvist G. Decreased heart rate variability may predict the progression of carotid atherosclerosis in type 2 diabetes. Clin Auton Res 2006 16 : 228 234.
39. Yokoyama H, Katakami N, Yamasaki Y. Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke 2006 37 : 2420 2427.
40. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 348 : 383 393.
41. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M et al. Long-term clinical effects of epalrelstat, an aldose reductase inhibitor, on diabetic peripheral neuropathy. The 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complication trial. Diabetes Care 2006 29 : 1538 1544.
42. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001 104 : 1464 1470.